U.S. Markets close in 4 hrs 57 mins
  • S&P 500

    3,255.27
    -54.84 (-1.66%)
     
  • Dow 30

    26,284.64
    -374.47 (-1.40%)
     
  • Nasdaq

    10,904.17
    -281.43 (-2.52%)
     
  • Russell 2000

    1,533.36
    -28.22 (-1.81%)
     
  • Crude Oil

    35.51
    -0.66 (-1.82%)
     
  • Gold

    1,880.80
    +12.80 (+0.69%)
     
  • Silver

    23.57
    +0.21 (+0.90%)
     
  • EUR/USD

    1.1689
    +0.0011 (+0.0935%)
     
  • 10-Yr Bond

    0.8480
    +0.0130 (+1.56%)
     
  • Vix

    39.62
    +2.03 (+5.40%)
     
  • GBP/USD

    1.2948
    +0.0024 (+0.1890%)
     
  • USD/JPY

    104.6030
    -0.0070 (-0.0067%)
     
  • BTC-USD

    13,354.96
    +56.11 (+0.42%)
     
  • CMC Crypto 200

    260.81
    -2.82 (-1.07%)
     
  • FTSE 100

    5,545.67
    -36.08 (-0.65%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 2095674. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and is in the process of filing an IND for a Phase 1 clinical trial for solid tumors. The Company is also developing BP1002, which targets the Bcl-2 protein and is expected to be evaluated for the treatment of lymphoma and solid tumors. In addition, BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, is expected to enter Phase 1 studies in 2020.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369